Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06591806 · ClinicalTrials.gov registry record

An Observational Study in Children and Adults With Stargardt Disease

A clinical trial of Stargardt Disease, sponsored by AAVantgarde Bio Srl.

Recruiting
Registry status
80
Enrollment target
2
Study locations

NCT06591806 is a study of Stargardt Disease that is actively recruiting participants, run by AAVantgarde Bio Srl. The registered enrollment target is 80 participants, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06591806, a study of Stargardt Disease, is actively recruiting participants, sponsored by AAVantgarde Bio Srl.

RECRUITING
Registry status
80 participants
Enrollment target
2
Study locations

Study Summary

This multicenter, prospective, longitudinal, observational study in approximately 80 subjects with Stargardt disease secondary to biallelic mutations in the ABCA4 gene (STGD1) aims to evaluate prognostic factors of disease progression, and to further characterize the patient population for future clinical studies.

Conditions Studied

Study Locations (2)

Texas

  • Retina Foundation of the Southwest - Dallas

Other

  • Oslo University hospital Ullevål - Oslo

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-05-01
Est. Completion 2027-06-30

Sponsor

AAVantgarde Bio Srl

2 total trials

What the Registry Record Tells You About NCT06591806

The ClinicalTrials.gov registry entry for NCT06591806 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target. The listed sponsor is AAVantgarde Bio Srl, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stargardt Disease appearing as the primary indexed condition, and to 0 interventions.

NCT06591806 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.

Frequently Asked Questions

What is clinical trial NCT06591806 about?

NCT06591806 is a clinical study titled "An Observational Study in Children and Adults With Stargardt Disease". This multicenter, prospective, longitudinal, observational study in approximately 80 subjects with Stargardt disease secondary to biallelic mutations in the ABCA4 gene (STGD1) aims to evaluate prognostic factors of disease progression, and to further characterize the patient population for future cl...

What is the current status of trial NCT06591806?

This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2024-05-01. Estimated completion is 2027-06-30.

What conditions does trial NCT06591806 study?

This clinical trial studies the following conditions: Stargardt Disease.

Who is sponsoring clinical trial NCT06591806?

This trial is sponsored by AAVantgarde Bio Srl, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06591806 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stargardt Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.